title: Update on pathology, staging and molecular pathology of endometrial (uterine corpus) adenocarcinoma.
abstract: Endometrial carcinoma is comprised of two major groups: type I that is hormonally driven with a good prognosis and type II that is hormone independent with a poor prognosis. The two most common subtypes are endometrioid adenocarcinoma, the prototypic type I cancer, and uterine serous carcinoma, the prototypic type II cancer, each with their own distinct precursor lesion. The histologic type, as codified by the WHO Tumor Classification system, grade, and stage are used to guide treatment. There is an increasing interest in screening for familial risk factors, specifically Lynch syndrome. A molecular classification of endometrial cancers holds promise for future improvements in care.
authors.affiliation: Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, 8700 Beverly Blvd, Los Angeles, CA 90048, USA.
authors.forename: Joanne K L
authors.initials: JK
authors.lastname: Rutgers
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000209:etiology* / Q000378:metabolism / Q000473:pathology*; D018284:Cystadenocarcinoma, Serous; D016889:Endometrial Neoplasms / Q000175:diagnosis / Q000209:etiology* / Q000378:metabolism / Q000473:pathology*; D058750:Epithelial-Mesenchymal Transition; D005260:Female; D006801:Humans; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011230:Precancerous Conditions; D012307:Risk Factors
keywords: endometrial carcinoma; molecular subtypes; pathology; uterine cancer